ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, usual dosage and administration, relative contraindications, clinically significant drug interactions, adverse drug reactions and overdosage of Mirtazapine. The ingestion of food has no significant effect on the bioavailability of mirtazapine. Peak blood levels are obtained within 2 hours. Mirtazapine is moderately bound to plasma proteins and is extensively metabolized in the liver. Mirtazapine pharmacotherapy has been associated with the development of severe neutropenia , a potentially fatal reduction in the blood neutrophil count, often resulting in an increased susceptibility to bacterial and fungal infections. Prescribe mirtazapine pharmacotherapy cautiously to patients who have cardiovascular disorders, such as arteriosclerosis or hypercholesterolemia. Concurrent mirtazapine pharmacotherapy may increase the CNS depression associated with alcohol use. Advise patients to avoid, or limit, their use of alcohol while receiving mirtazapine pharmacotherapy. Signs and symptoms of mirtazapine overdosage include disorientation, drowsiness, memory impairment, and tachycardia.
